Dipyridamole Specifically Decreases Platelet-Derived Growth Factor Release from Platelets
- 1 January 1990
- journal article
- research article
- Published by S. Karger AG in Pharmacology
- Vol. 40 (3) , 150-156
- https://doi.org/10.1159/000138653
Abstract
We previously reported that dipyridamole decreased platelet-derived growth factor (PDGF) levels in human serum by lowering the release of PDGF during blood clotting. In this study, we have shown that this effect is specific for dipyridamole, and is not shown in other anti-platelet drugs such as aspirin, trapidil or ticlopidine. In addition, dipyridamole has been shown to decrease the PDGF level selectively, but not the levels of other factors from .alpha.-granules in platelets (.beta.-thromboglobulin and platelet factor IV). These data indicate that dipyridamole may be an effective drug for preventing PDGF-related disorders.This publication has 7 references indexed in Scilit:
- Dipyridamole decreases platelet-derived growth factor levels in human serum.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1987
- sis (platelet-derived growth factor B chain) gene transcript levels are elevated in human atherosclerotic lesions compared to normal artery.Proceedings of the National Academy of Sciences, 1987
- Human plasma epidermal growth factor/beta-urogastrone is associated with blood platelets.Journal of Clinical Investigation, 1983
- Dipyridamole Inhibits Platelet Aggregation in Whole BloodThrombosis and Haemostasis, 1983
- Serum contains a platelet-derived transforming growth factor.Proceedings of the National Academy of Sciences, 1982
- Purification of human platelet-derived growth factor.Proceedings of the National Academy of Sciences, 1979
- Influence of a Pyrimidopyrimidine Derivative on Deamination of Adenosine by BloodCirculation Research, 1964